News

The combination therapies will be evaluated in two Phase I/II trials by Novartis in patients with non-small cell lung cancer (NSCLC). Novartis’ three molecularly targeted oncology therapies include

The recommended dosage of EYLEA in patients with macular edema following RVO is 2mg every four weeks. Regeneron chief scientific officer George Yancopoulos said RVO is a significant

NER1006 is a low volume polyethylene glycol based bowel preparation developed to provide whole bowel cleansing, with an additional focus on the ascending colon. The multicenter, randomized, parallel-group

The company has started this voluntary recall to the user level due to labeling the product with the incorrect expiration date, which is longer than the known stability

The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products that show promise for the diagnosis and/or treatment of rare

As part of the deal, Lee’s Pharma will have exclusive rights to develop and commercialize the antibody for the Chinese market, including Mainland China, Hong Kong, Macau, and

The acquisition will see ClinIntel’s offerings combined into the ClinPhone RTSM suite and are designed to make patient randomization and clinical supply chain solutions more efficient. ClinIntel’s capabilities

Under the terms of the agreement, Baxter will become the exclusive distributor of Rockwell’s hemodialysis concentrate and ancillary products in the U.S. and selected foreign countries for an

"We are pleased to enter into this strategic partnership and are excited by the opportunity to couple Intrexon’s market-leading expertise in synthetic biology with our proficiency in cell